Abbvie (ABBV)
NYSE:ABBV
Want to see ABBV full AI Analyst Report?
ABBV Stock Chart & Stats
$208.38
-$1.97(-1.10%)
At close: 4:00 PM EST
$208.38
-$1.97(-1.10%)
Day’s Range― - ―
52-Week Range$181.73 - $244.81
Previous CloseN/A
Volume1.02M
Average Volume (3M)6.22M
Market Cap
$383.62B
Enterprise Value$447.89B
Total Cash (Recent Filing)$9.39B
Total Debt (Recent Filing)$72.86B
Price to Earnings (P/E)109.6
Beta0.23
Next Earnings
Jul 24, 2026EPS Estimate
3.76Next Dividend Ex-DateN/A
Dividend Yield2.87%
Share Statistics
EPS (TTM)2.04
Shares Outstanding1,766,792,800
10 Day Avg. Volume5,445,065
30 Day Avg. Volume6,219,402
Financial Highlights & Ratios
PEG Ratio-77.01
Price to Book (P/B)-124.40
Price to Sales (P/S)6.65
P/FCF Ratio22.83
Enterprise Value/Market Cap1.17
Enterprise Value/Revenue7.13
Enterprise Value/Gross Profit10.09
Enterprise Value/Ebitda26.47
Forecast
1Y Price Target
$256.47Price Target Upside23.08% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering20
EPS Forecast (FY)14.24
Revenue Forecast (FY)$67.28B
Bulls Say, Bears Say
Bulls Say
Cash-generation StrengthAbbVie’s large, growing free cash flow (TTM ~ $20.9B, +11.6%) is a durable structural strength: it funds R&D, manufacturing buildouts, dividends and BD activity without reliance on near-term equity or asset sales. Strong cash conversion supports strategic flexibility over coming quarters.
Immunology Commercial MomentumRapid, sustainable growth in Skyrizi and Rinvoq indicates successful portfolio transition as Humira wanes. Durable uptake across psoriasis, IBD and other indications underpins revenue resiliency and reduces concentration risk over the next 2–6 months as launches and label expansions progress.
Pipeline Progress And Capacity InvestmentRegulatory submissions, positive interim data and parallel manufacturing investments are structural positives: they expand future addressable markets and reduce launch bottlenecks. Combined clinical and capacity progress improves probability of durable commercial ramp for new indications.
Bears Say
Heavy LeverageVery high absolute and relative debt levels materially constrain strategic flexibility: interest and refinancing risk rise, credit-sensitive spends become harder to scale, and management’s capital allocation (M&A, buybacks) faces limits if earnings dip over the next several quarters.
Compressed Net MarginsSharp fall in net margin versus prior years signals persistent non-operating costs, acquired IPR&D impacts, and price/competitive pressure. Lower bottom-line elasticity reduces cushion for earnings shocks and weakens ability to deleverage quickly even with strong cash flow.
HUMIRA Biosimilar ErosionContinued Humira revenue decline from biosimilar entry is a structural headwind to near-term revenue stability. The transition places pressure on absolute top-line levels and increases reliance on ramping newer franchises to replace lost scale within the next 2–6 months.
AbbVie News
ABBV FAQ
What was Abbvie’s price range in the past 12 months?
Abbvie lowest stock price was $181.73 and its highest was $244.81 in the past 12 months.
What is Abbvie’s market cap?
Abbvie’s market cap is $383.62B.
When is Abbvie’s upcoming earnings report date?
Abbvie’s upcoming earnings report date is Jul 24, 2026 which is in 49 days.
How were Abbvie’s earnings last quarter?
Abbvie released its earnings results on Apr 29, 2026. The company reported $2.65 earnings per share for the quarter, beating the consensus estimate of $2.592 by $0.058.
Is Abbvie overvalued?
According to Wall Street analysts Abbvie’s price is currently Undervalued.
Does Abbvie pay dividends?
Abbvie pays a Quarterly dividend of $1.73 which represents an annual dividend yield of 2.87%. See more information on Abbvie dividends here
What is Abbvie’s EPS estimate?
Abbvie’s EPS estimate is 3.76.
How many shares outstanding does Abbvie have?
Abbvie has 1,766,792,800 shares outstanding.
What happened to Abbvie’s price movement after its last earnings report?
Abbvie reported an EPS of $2.65 in its last earnings report, beating expectations of $2.592. Following the earnings report the stock price went up 3.136%.
Which hedge fund is a major shareholder of Abbvie?
Currently, no hedge funds are holding shares in ABBV
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
AbbVie Stock Smart Score
Outperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$256.47 (23.08% Upside)
$256.47 (23.08% Upside)
Blogger Sentiment
Bullish
ABBV Sentiment 70%
Sector Average ―
Sector Average ―
Hedge Fund Trend
Increased
By 8.7M Shares
Last Quarter.
Last Quarter.
Insider Transactions
Sold Shares
Worth $1.2M over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Neutral
Last 7 Days ▼ 0.4%
Last 30 Days ▲ 1.0%
Last 30 Days ▲ 1.0%
News Sentiment
Very Bullish
Bullish news 99%
Bearish news 0%
Bearish news 0%
Technicals
SMA
Negative
20 days / 200 days
Momentum
23.98%
12-Months-Change
Fundamentals
Return on Equity
68.01%
Trailing 12-Months
Asset Growth
0.22%
Trailing 12-Months
Company Description
Abbvie
AbbVie Inc. discovers, develops, manufactures, and sells pharmaceuticals in the worldwide. The company offers HUMIRA, a therapy administered as an injection for autoimmune and intestinal Behçet's diseases; SKYRIZI to treat moderate to severe plaque psoriasis in adults; RINVOQ, a JAK inhibitor for the treatment of moderate to severe active rheumatoid arthritis in adult patients; IMBRUVICA to treat adult patients with chronic lymphocytic leukemia (CLL), small lymphocytic lymphoma (SLL), and VENCLEXTA, a BCL-2 inhibitor used to treat adults with CLL or SLL; and MAVYRET to treat patients with chronic HCV genotype 1-6 infection. It also provides CREON, a pancreatic enzyme therapy for exocrine pancreatic insufficiency; Synthroid used in the treatment of hypothyroidism; Linzess/Constella to treat irritable bowel syndrome with constipation and chronic idiopathic constipation; Lupron for the palliative treatment of advanced prostate cancer, endometriosis and central precocious puberty, and patients with anemia caused by uterine fibroids; and Botox therapeutic. In addition, the company offers ORILISSA, a nonpeptide small molecule gonadotropin-releasing hormone antagonist for women with moderate to severe endometriosis pain; Duopa and Duodopa, a levodopa-carbidopa intestinal gel to treat Parkinson's disease; Lumigan/Ganfort, a bimatoprost ophthalmic solution for the reduction of elevated intraocular pressure (IOP) in patients with open angle glaucoma (OAG) or ocular hypertension; Ubrelvy to treat migraine with or without aura in adults; Alphagan/ Combigan, an alpha-adrenergic receptor agonist for the reduction of IOP in patients with OAG; and Restasis, a calcineurin inhibitor immunosuppressant to increase tear production, as well as other eye care products. AbbVie Inc. has a research collaboration with Dragonfly Therapeutics, Inc. The company was incorporated in 2012 and is headquartered in North Chicago, Illinois.
ABBV Earnings Call
Q1 2026
0:00 / 0:00
Earnings Call Sentiment|Positive
The call conveyed strong commercial momentum and financial performance with multiple product growth drivers (Skyrizi, Rinvoq, neuroscience portfolio) and a raised full-year outlook. Substantial pipeline progress (regulatory submissions, combination Crohn's data, obesity signal) and major manufacturing investments reinforce long-term growth positioning. Offsets include expected HUMIRA biosimilar erosion, pressure in some oncology and aesthetic segments, selected clinical setbacks/non-differentiation and near-term acquired IPR&D expense impacts. On balance, highlights — including robust sales beats, double-digit growth for key franchises, guidance raise, and encouraging pipeline readouts — outweigh the lowlights.View all ABBV earnings summariesABBV Net revenue Breakdown
47.36% Immunology
15.97% Neuroscience
11.86% Other Key Products
11.64% Oncology
13.17% Other
ABBV Stock 12 Month Forecast
Average Price Target
$256.47
▲(23.08% Upside)
Technical Analysis
Ownership Overview
0.06% Insiders
20.68% Mutual Funds
― Other Institutional Investors
56.16% Public Companies and Individual Investors